Master protocol trials in oncology: Review and new trial designs

Akihiro Hirakawa\textsuperscript{a,}*, Junichi Asano\textsuperscript{b}, Hiroyuki Sato\textsuperscript{b}, Satoshi Teramukai\textsuperscript{c}

\textsuperscript{a} Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8654, Japan
\textsuperscript{b} Biostatistics Group, Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, 100-0013, Japan
\textsuperscript{c} Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan

ABSTRACT

In oncology, next generation sequencing and comprehensive genomic profiling have enabled the detailed classification of tumors using molecular biology. However, it is unrealistic to conduct phase I–III trials according to each sub-population based on patient molecular subtypes. Common protocols that assess the combination of several molecular markers and their targeted therapies by means of multiple sub-studies are required. These protocols are called “master protocols,” and are drawing attention as a next-generation clinical trial design. Recently, several reviews of clinical trials based on the master protocol design have been published, but their definitions of these such trials, including basket, umbrella, and platform trials, were not consistent. Concurrently, the acceleration of the development of new statistical designs for master protocol trials has been underway. This article provides an overview of recent reviews for master protocols, including their statistical design methodologies in Oncology. We also introduce several examples of previous and on-going master protocol trials along with their classifications by some recent studies.

1. Introduction

In oncology, next generation sequencing and comprehensive genomic profiling have enabled detailed classification of tumors using molecular biology. With this development, targeted therapies are being established for some tumor types based on genetic mutations [1–9]. If patient groups of the same tumor type (for example, gastric, lung, breast, or colorectal cancer) are classified by molecular subtypes, such as by genetic mutation, then patient groups can be further subdivided into unique subgroups. However, it is unrealistic to conduct phase I–III trials according to each subpopulation [10–12]. Common protocols that assess the combination of several molecular markers and their targeted therapies by means of multiple sub-studies are required for single and/or multiple tumor types. These protocols are called “master protocols,” and are drawing attention as a next-generation clinical trial design.

Three challenges that have been particularly difficult in common clinical trials are possibly alleviated by conducting multiple clinical trials based on a master protocol [13]. First, inter-patient and intra-patient heterogeneity can be evaluated efficiently [14]. Identical tumor types can exhibit different responses to treatments depending on patient characteristics or disease stage, and even within the same patient, differences in the type of cancer cells within the tumor tissue can also generate a different treatment response. In trials using a master protocol, trial data from multiple sub-studies can be comprehensively used to evaluate inter- and intra-patient heterogeneity. Second, findings on specific signal pathways strongly associated with driver gene mutations and cancer cell growth and progression can be obtained [15–17]. Third, combining two or more targeted therapies makes it possible to expand the genetic mutations being studied [18–20].

This article begins with an overview of the history from biomarker-based trial design to master protocol trial, and subsequently summarizes clinical trials using master protocols in oncology based on recent general theories of master protocol design [21–23]. We introduce several examples of master protocol trials along with their classifications according to previous studies. We also discuss new statistical designs for basket trials, including designs that use the recently developed response-adaptive randomization, in addition to discussing the future direction of master protocol trials.

2. Changes from biomarker-based to master protocol trial design

In order to understand the motivation and concept of clinical trial design using a master protocol, we first introduce the clinical trial designs that use molecular markers, along with their history in cancer treatment. In oncology, patients are generally classified by their primary cancer and stage, and randomized controlled trials are conducted

* Corresponding author. Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8654, Japan.

E-mail address: hirakawa@m.u-tokyo.ac.jp (A. Hirakawa).

https://doi.org/10.1016/j.conctc.2018.08.009
Received 20 April 2018; Received in revised form 10 August 2018; Accepted 23 August 2018
Available online 24 August 2018
2451-8654/ © 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
for each patient population to create standard therapies. Historically, cytotoxic agents have been developed based on this perspective. However, research and development in the 2000s enabled cancer cell growth and progression to be defined at cellular and molecular levels, and the presence or absence of molecular markers or genetic mutations enabled classification of particular tumor types into several subtypes. At the same time, there were developments in the chemotherapeutic drugs available, shifting from treatments centered on cytotoxic agents to those using molecularly targeted agents, which act selectively on cancer cells. Recently, there is active research on immune checkpoint inhibitors, which attack cancer cells by utilizing a patient's immune response. Molecularly targeted agents that target specific molecular markers include gefitinib and erlotinib for EGFR gene mutation-positive inoperable, recurrent, or metastatic non-small cell lung cancer [5,24], as well as crizotinib, alectinib, and ceritinib for ALK fusion gene-positive non-small cell lung cancer [6–8,25]. Immune checkpoint inhibitors presently include nivolumab and pembrolizumab [26,27].

Clinical trial designs based on molecular markers began to gain popularity with the aforementioned changes in chemotherapy agents. Trial designs called “enrichment designs” or “targeted designs” are studies where patient populations with a single molecular marker for which a drug's effects can be expected in a specific tumor type (in this paper, we will assume that it is effective for the marker-positive population). This design is selected on the premise that: i) the molecular marker is an established marker, which is strongly correlated with the efficacy of an investigational drug; ii) it has been biologically demonstrated that drug efficacy cannot be expected in the marker-negative cases; and iii) that a diagnostic tool for evaluating molecular marker status has been developed. Clinical trials using the enrichment design have included a clinical trial of trastuzumab [1], the N9831 trial for HER2-positive breast cancer [28], and the ToGA trial on HER2-positive stomach cancer [11]. If the molecular marker is not established as a reliable marker, the use of a marker-stratified design may be considered. In this design, patients were assigned to arms by molecular marker positivity or negativity, and were randomized within each arm. Clinical trials that used the marker-stratified design include the INTEGRON [29] and MARVEL [30] trials. After this type of design was introduced, sequential subgroup-specific, marker sequential test (MaST) and fallback designs were proposed as extensions of the marker-stratified design [31]; this eventually led to the proposal of clinical trials that use the master protocol design.

3. Master protocol trial

3.1. Definition and characteristics

A master protocol is a comprehensive protocol created for evaluating multiple hypotheses of sub-studies that are concurrently conducted. This comprehensive protocol comprises different sub-protocols of multiple concurrently-operating sub-studies (Fig. 1), where the sub-studies are commonly conducted on populations based on specific tumor types, histologic types, and/or molecular markers. We will refer to these types of trials as “master protocols.”

A master protocol trial uses a common system for patient selection, logistics, templates, and data management [22]. Histologic and hematologic specimens of patients enrolled in master protocol trials are also measured and analyzed using a common basic system (e.g., next generating sequence and immunohistochemistry) to collect coherent molecular marker data. Patients can participate in sub-studies for which they meet eligibility criteria based on their molecular marker data. Thus, enrolling in a master protocol trial increases the chance of participation in a trial that is most suitable for a given patient. Even if there are no sub-studies that a given patient can participate in, they will be followed-up, and can be placed on a waiting list until an appropriate sub-study is started. Furthermore, natural history data from a waiting-list can be used as controls in evaluating the efficacy of an investigational drug in a single-arm sub-study.

3.2. Trial purpose

Master protocol trials can be exploratory or confirmatory [10,32–34]. Exploratory master protocol trials are often composed of multiple single-arm sub-studies, and confirmatory master protocol trials are composed of multiple randomized sub-studies. For either trial type, the design and statistical considerations are commonly standardized between all sub-studies.

3.3. Advantages and challenges

The advantages of a master protocol trial are related to the fact that they include data from sub-populations on a broad range of molecular markers. In comparison with the marker-based trials described in Section 2, two advantages appear in the master protocol trials. First, this enables efficient enrollment of rare fraction patients so that centralized patient management, based on a common protocol, promotes the acceleration of clinical development. Second, master protocol trials are beneficial for patients as well because they increase the chance of trial participation for which they can expect optimal therapeutic effects. On the other hand, the challenges associated with master protocol trials, include the fact that several small sub-studies are being conducted in parallel, which may increase the rate of false positive findings.

4. Basket, umbrella, and platform trials

4.1. Definitions

A master protocol trial is often classified into basket, umbrella, and platform trials based on characteristics of the study population (e.g., disease, histologic type, molecular marker) and on both the type and number of study therapies. The common definitions of each trial type based on literature [22,23] are shown in Table 1. However, as pointed out by Renfro and Sargent [23], the definitions of each trial type are not standardized [10,20,35–37], with possible overlaps between them that should be noted. For example, the NCI-MATCH trial, which will be mentioned in a later section, is a type that has aspects of both basket and umbrella trials. In this article, we will organize the trial types by definitions given in recent works [21–23].

4.2. Basket trials

A basket trial evaluates one targeted therapy on multiple diseases or multiple disease subtypes. In oncology, this is exemplified by examining the therapeutic effects of molecularly targeted agents for several tumor types that may have a common single molecular marker, or genetic mutation, by tumor type and/or across tumor types (Fig. 2). In this scenario, the grouped tumor types form a basket, and sub-studies are conducted by tumor groups within it. Basket trials are often conducted as single-arm, phase II trials with the purpose of evaluating proof-of-concept (POC) in an early stage of development. Generally, the number of participants in individual sub-studies are between 20 and 50, and hypotheses that can demonstrate statistical significance are made only when there is major therapeutic efficacy; therefore, a basket trial is considered a “signal-finding” trial. As for sub-study design, two-stage or multi-stage designs may be used. As such, basket trials are characterized by the comprehensive execution of single-arm trials with a small number of patients, which enables efficient patient enrollment for rare cancers or rare fractions. However, it should be noted that basket trials have the assumption that they allow a fairly accurate prediction of whether a tumor with particular molecular characteristics will respond to a targeted therapy; furthermore, such response to a targeted therapy is established irrespective of the histologic type of the tumor. Moreover,
patients enrolled in each sub-study are often composed of a heterogeneous group in terms of tumor type, histologic type or patient characteristics. Therefore, as it is difficult to evaluate time-to-event end-points (e.g., progression-free survival or overall survival), primary endpoints are often response rates, which are less sensitive to the effects of population heterogeneity. The absence of a control group is a limitation in evaluating therapeutic effect; thus, it is desired to collect control data.

4.3. Umbrella trials

Umbrella trials evaluate multiple targeted therapies for one disease or several diseases (e.g., that are expected to respond to an investigational drug). In oncology, sub-studies are conducted to evaluate targeted therapies that correspond to different molecular markers or genetic mutations within a particular tumor type. In that case, the tumor type is the “umbrella,” under which sub-studies for each molecular marker are operated (Fig. 3). Sub-studies may be single arm, phase II, or phase II/III trials that are randomized and compared to placebo or a standard therapy. Umbrella trials have in common a system that unifies molecular profiles of patient specimens for evaluation. While basket trials are generally single-arm sub-studies that are exploratory in nature, umbrella trials are often single-arm or randomized sub-studies that are confirmatory. Therefore, a randomized sub-study with appropriate eligibility criteria by tumor type and/or stage can generate confirmatory evidence related to the targeted therapy for the tumor type under study. However, patient enrollment may be slowed in the case of compartmentalization by molecular markers for examining rare cancers or rare fractions. In addition, umbrella trials are normally large-
scale and long-term master protocol trials, but when the standard therapy changes during that period, the clinical significance of comparing to a control group of patients undergoing standard therapy is lost [10,20]. Hyman et al. [35] have termed umbrella trials as "molecular allocation studies."

4.4. Platform trials

Platform trials evaluate several targeted therapies for one disease perpetually, and further accept additions or exclusions of new therapies or patient populations during the trial. Basket and umbrella trials could also be considered platform trials, if they permit the addition or exclusion of new treatments during the trial. In a platform trial, interim analyses evaluate the efficacy or futility of each targeted therapy, and their results are used to exclude certain targeted therapies or to add new ones. Futility is often evaluated by the Bayesian method [33,35,38]. Since sub-studies by molecular markers are not mutually independent trials, the efficacy of the targeted therapy of each sub-study can be estimated by a Bayesian hierarchical model [23]. As such, platform trials permit relatively flexible addition or exclusion of treatment methods or patient populations, thereby enabling an efficient transition to a confirmatory trial. Challenges of the platform trial include its large-scale, long-term nature, associated high costs of managing and executing the trial, and the need to build organizations or frameworks that can operate these trials perpetually.

5. Example trials

Table 2 lists examples of basket trials, umbrella trials, and platform trials found in the literature. As mentioned above, the distinctions between each are not clear-cut; therefore, it should be noted that different authors may categorize these trials differently. An overview of several of these trials follows.

5.1. Study B2225

Study B2225 enrolled patients with 40 different solid tumors or hematologic malignancies, without limiting molecular markers to evaluate the efficacy of imatinib [39]. The sample size for each tumor type was not determined in advance, but patients were enrolled competitively. Although it did not begin as a basket trial, it is categorized as a basket trial by Woodcock and LaVange [22] because it studied multiple tumor types for one drug.

5.2. BRAF-V600 study

The BRAF-V600 study is a trial comprising multiple sub-studies to evaluate the efficacy of vemurafenib for non-melanoma BRAF V600E mutation-positive cancers [40]. Hyman et al. [40], Cunanan et al. [21], and Woodcock and LaVange [22] all classified this study as a basket trial. The sample size for each sub-study is determined by the Simon two-stage design.

5.3. AcSé trial

The AcSé (Accès Sécurisé à des thérapies ciblées innovantes) is an ongoing trial composed of 23 sub-studies that evaluate the efficacy of crizotinib monotherapy for several tumor types associated with ALK, MET, RON, and ROS1 mutations [20]. Menis et al. [20] reviewed the master protocol trial on thoracic malignancies and categorized the AcSé trial as a basket trial. The associated sub-studies were typically based on a two-stage design.

5.4. NCI-MATCH trial

The NCI-MATCH (NCI Molecular Analysis for Therapeutic Choice) trial is composed of 24 sub-studies that evaluate the efficacy of at least 17 targeted therapies for solid tumors and lymphomas that were treated with at least one regimen [41]. The primary endpoint for each sub-study is response rate. Thirty-five patients were enrolled in this single-arm design trial, based on a binomial distribution, and the key secondary endpoint was the 6-month progression-free survival. Woodcock and LaVange [22] categorized the NCI-MATCH trial as an umbrella trial, but Renfro and Sargent [23] categorized it as a basket trial.

5.5. ALCHEMIST trial

ALCHEMIST (The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) trial is a randomized umbrella trial on ALK- or EGFR-positive, high-risk lung adenocarcinoma patients [42]. ALK- or EGFR-positive patients are enrolled in a phase III randomized sub-study comparing crizotinib to placebo, or a randomized sub-study comparing erlotinib to placebo. The primary endpoint of each trial is overall survival and an interim analysis is planned. In patients who are both ALK- and EGFR-negative, PD-L1 expression is measured and they are considered for enrollment in a randomized sub-study that compares nivolumab administration group to an observation group. The primary
Table 2
Examples of master protocol trials in oncology.

| Trial name | Design | Targeted drug | Main diseases | target | Number of patients | Endpoint | Woodcock & LaVange [22] | Cunanan et al. [21] | Renfro & Sargent [23] | Renfro & Mandrekar [13] |
|------------|--------|---------------|---------------|--------|-------------------|----------|------------------------|-------------------|-------------------|------------------------|
| B2225      | Ph2 (phase 2), multi-center, unblinded, uncontrolled | Imatinib | 40 carcinomas (solid, hematologic) | – | 186 | Response rate | basket | – | – | – |
| BRAF V600  | Ph2, multi-center, unblinded, uncontrolled | Vemurafenib, cetuximab | Multiple carcinomas | BRAF V600 | 122 | Response rate | basket | basket | – | – |
| AcS        | Ph2, multi-center, unblinded, uncontrolled | Crizotinib | Gastrointestinal, breast, cancer, ovarian, thyroid cancers, sarcoma, etc. | ALK, MET, RON, ROS1 | 488 | Response rate | – | – | basket | – |
| NCI-Match  | Ph2, multi-center, uncontrolled | 30 approved and unapproved treatments targeting genetic mutations | Advanced solid tumors, lymphomas, myelomas (mutation measured) | EGFR, MET, ALK, ROS1, BRAF V600, mTOR, etc. | 35/sub-study | Response rate, PFS rate | umbrella | – | basket | basket |
| ALCHEMIST  | Ph3, multi-center, unblinded, randomized | Erlotinib, crizotinib, nivolumab | Pulmonary adenocarcinoma | EGFR, ALK, PD-L1 | ≥770 | OS, DFS | – | umbrella | umbrella | umbrella |
| LUNG-MAP   | Seamless Ph2/3, randomized | Erlotinib, ipilimumab, nivolumab, palbociclib, etc. | Squamous cell non-small cell lung carcinoma (NSCLC) | PIK3CA, FGFR, CDKN1, B2, CDK4, c-MET | 100-170 (Ph2) 300-400 (Ph3) | Response rate, PFS, OS | master protocol | – | umbrella |
| FOCUS4     | Ph2/3, multi-center, unblinded, randomized | Molecular target drugs such as BRAF inhibitors, etc. | Colorectal cancer | BRAF, PIK3CA, PTEN, KRAS, NRAS | Approx.2000 | PFS, OS | – | – | umbrella | platform |
| BATTLE-1   | Ph2, single-center, adaptive-randomized | Erlotinib, vandetanib, sorafenib, erlotinib + bexarotene | Advanced NSCLC | EGFR, KRAS, BRAF, VEGF, RXRs/CyclinD1 | 255 | Response rate, PFS, OS, toxicity | umbrella | – | platform | – |
| I-SPY 2    | Ph2, multi-center, adaptive-randomized | Pembrolizumab, trastuzumab, pertuzumab, neratinib, etc. | Early high-risk breast cancer | HR, HER2, MammaPrint | 1920 | Pathological response rate | platform | – | platform | – |
| SHIVA      | Ph2, multi-center, unblinded, randomized | Erlotinib, lapatinib + trastuzumab, sorafenib, dabatinib, vemurafenib, everolimus, abiraterone, letrazole, tamoxifen | Advanced tumors resistant to standard treatment | Hormone receptor, PI3K, PT, mTOR, RAF, MEK | 195 | PFS | – | – | platform, etc. | – |
| NCI-MPACT  | Ph2, multi-center, unblinded, randomized | PARP inhibitors, Wee 1 inhibitors, everolimus, trametinib | Advanced solid tumors | DNA repair, PI3K, RAS/RAF/MEK | 180 | Response rate, PFS rate | – | – | platform, etc. | – |
| CUSTOM     | Ph2, multi-center, unblinded, uncontrolled | Erlotinib, selumetinib, AKT inhibitors, lapatinib, soratinib | NSCLC, small cell lung carcinoma, thymic carcinoma | EGFR, KRAS, HRAS, NRAS, BRAF, PTEN, Akt 1, PIK3CA, ERBB2, KIT, PDGFA | 6-47 | Response rate | – | basket | platform, etc. | – |
| CREATE     | Ph2, multi-center, unblinded, uncontrolled | Crizotinib | Advanced cancers such as sarcomas | ALK, MET | 582 | Tumor regression | basket | platform, etc. | – |

OS: Overall survival, PFS: Progression-free survival, DFS: Disease-free survival.
endpoints for these sub-studies are overall survival and disease-free survival. Similar umbrella trials include the LUNG-MAP trial [23].

5.6. FOCUS4 trial

The FOCUS4 trial is a placebo-controlled multi-group multi-stage randomized trial to evaluate the efficacy of multiple targeted therapies for untreated colorectal cancer [43]. Safety is evaluated in stage 1, and POC is confirmed in stage 2, short-term outcomes evaluated in stage 3, and long-term efficacy is evaluated in stage 4 in a patient population with a particular molecular marker. The efficacy endpoints are progression-free survival and overall survival. A multi-group, multi-stage design like this trial allows for new treatments to be added during the trial and for exclusion of treatments that have been confirmed to be futile before entering stage 3 or 4, which corresponds to phase III. This is the reason Renfro and Sargent [23] categorize the FOCUS4 trial as an umbrella trial, whereas Renfro and Mandrekar [13] have noted that it can also be classified as a platform trial. Patients who are negative or wild-type for all molecular markers can also enroll in the FOCUS4 trial.

The BATTLE-1 [44–46], I-SPY 2 [47,48], SHIVA [49], and CUSTOM [50] trials are often referenced as examples of platform trials in reviews on master protocol trials.

6. New trial designs in master protocol trials

A basket trial may include a single-arm sub-study for several tumor types with the same molecular marker, with response rate as the primary endpoint for a given tumor type. Occasionally, an interim analysis during the trial will discover that a sub-study for a tumor type with an extremely low response rate should be terminated early due to a lack of therapeutic effect. In addition to evaluating the response rate of each sub-studies, sometimes it is of interest to evaluate response rates across different tumor types. Recently, several authors have developed a new methodology for the basket design to accommodate these requirements. In this section, we overview these methods along with the existing approaches that can be used for the design of basket trials.

Before the emergence of master protocol trials, some statistical designs for single-arm trials that included multiple sub-populations have been proposed. As frequentist designs, LeBlanc et al. [51] proposed the frequentist strategy, including both analyses for each stratum, as well as a combined analysis that borrows information from all trial patients. Regarding Bayesian designs, Thall et al. [52] and Berry et al. [53] proposed the use of Bayesian hierarchical modeling, which borrows information across sub-populations. For example, the basket trial (NCT02034110) investigating the efficacy of combined dabrafenib and trametinib therapy for rare cancers with BRAF-V600 gene mutations estimated the response rate using the Bayesian hierarchical model. However, Freidlin and Korn [54] reported that in the phase II setting, the hierarchical Bayesian approach did not work well in the simulations.

The exchangeability–nonexchangeability (EXNEX) method, which is a robust mixture extension of the standard EX approach and allows each stratum-specific parameter to be exchangeable with other similar strata parameters or nonexchangeable with any of the similar parameter. Simon et al. [56,57] developed a different kind of Bayesian design using two parameters, which one is specified as the prior probability that the response in each stratum is considered desirable activity and one is specified as the prior probability that the response probabilities are equal across strata. More recently, Chu and Yuan [58] developed the Bayesian latent subgroup design (BLAST), which accounts for patient heterogeneity. In frequentist approaches, Cunanan et al. [59] modified the method of using independent Simon two-stage designs for each basket to improve the overall efficiency of the trial overall. A hybrid design that combines the Bayesian and frequentist models (hybrid design) [60], has also been proposed. In this design, if the homogeneity of treatment effect among strata is not rejected at an interim analysis, the hierarchical Bayesian model is used at the final analysis. More recently, Chu and Yuan [61] developed a calibrated Bayesian hierarchical model approach to evaluate the treatment effect based on binary endpoint. Apart from these single-arm designs, several authors proposed other designs with different perspectives. For example, Yuan et al. [63] and Chen et al. [64] focused on the control of the family-wise error rate in basket trials with pruning. Response-adaptive randomization is also discussed in the literature [65,66].

In contrast to the basket trials, new designs for the umbrella and platform designs have been little studied. In the platform trials such as BATTLE and I-SPY2 trials, adaptive randomization and the Bayesian hierarchical models was used for evaluating the treatment effects [48,62,67]. Hobbs et al. [38] and Kaizer et al. [68] developed new Bayesian modeling and adaptive randomization for platform design. Ghosh et al. [69] developed the frequentist approach for platform trial, which guarantees strong control the type-1 error rate. Simon [62] reviewed some of the umbrella, basket, and platform designs and suggested using enrichment designs for phase II/III umbrella trials.

Response-adaptive randomization may also be used in the umbrella and platform trial types. However, it must be noted that there are many debates on response-adaptive randomization that are independent of the various problems associated with master protocol trials. Previous reports have discussed the designs of platform trials, including adaptive randomization [70–72].

7. Summary and prospects

The randomized controlled trial is the gold standard for establishing standard treatments. In principle, randomized controlled trials evaluate the safety and efficacy of one therapy for one disease, and are designed to evaluate a pre-established statistical hypothesis. However, the rising costs of operating clinical trials, including randomized controlled trials, have limited the feasibility of conducting randomized controlled trials for all important clinical hypotheses. To overcome this problem, new experimental designs and methods of data analysis have been developed to efficiently evaluate single or multiple hypotheses. For example, the group sequential design, sample size re-estimation, and adaptive designs, such as the seamless phase II/III design [73], can be considered as trial designs for evaluating hypotheses efficiently.

In oncology, new clinical trials that use basket, umbrella, platform, or other master protocols are expected to increase due to the focus on genomic medicine. Clinical trials using master protocols are increasing in the non-Oncology setting as well. These include the REMAP-CAP (Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia) trial [74] in the area of bacterial and viral diseases, the ALICÈ (Antivirals for influenza Like Illness? A Ct of Clinical and Cost effectiveness in primary Care) trial [75] for influenza like illness, the PREVAIL II (the Partnership for Research on Ebola Virus in Liberia II) trial for Ebola [76], and the EPAD LCS (the European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study) [77]) and the DIAN-TU NexGen (the Dominantly Inherited Alzheimer Network Trials Unit Next Generation) trials [78] of mental and neurological diseases.

In recent years, there have been drugs for which efficacy was not observed in a broad study population, but they did demonstrate marked efficacy in specific patients. These patients are called “exceptional responders” [79], and new initiatives are in place to elucidate their molecular profiles. Master protocol trials can also be used to identify exceptional responders and are anticipated to become one of the standard clinical trial designs to promote individualized medical care.
Funding

This work was partially supported by the Grant-in-Aid for Scientific Research [grant number 17K00045] from the Japan Society for the Promotion of Science.

Acknowledgement

The views expressed in this article are those of the authors and do not necessarily reflect the official views of Pharmaceuticals and Medical Devices Agency.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.concton.2018.08.009.

References

[1] D.J. Slamon, et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med. 344 (2001) 783–792.

[2] D.J. Jonker, et al., Cetuximab for the treatment of colorectal cancer, N. Engl. J. Med. 357 (2007) 2040–2048.

[3] R.G. Armato, et al., Wild-type KRAS is required for panitumumab efficacy in patients with KRAS wild-type non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study, Lancet Oncol. 12 (2011) 735–742.

[4] A.T. Shaw, et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N. Engl. J. Med. 368 (2013) 2385–2394.

[5] A.T. Shaw, et al., Crizotinib in ROS1-rearranged nonsmall-cell lung cancer, N. Engl. J. Med. 371 (2014) 1963–1971.

[6] A.T. Shaw, et al., Ceritinib in ALK-rearranged nonsmall cell lung cancer, N. Engl. J. Med. 370 (2014) 1189–1197.

[7] S.M. Swain, et al., Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, N. Engl. J. Med. 372 (2015) 724–734.

[8] M.W. Redman, C.J. Allegra, The master protocol concept, Semin. Oncol. 42 (2015) 2521–2532.

[9] E.A. Perez, et al., Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31, J. Clin. Oncol. 25 (2011) 3366–3373.

[10] E.S. Kim, et al., Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial, Lancet 372 (2008) 1809–1818.

[11] B. Friedlin, L.M. McShane, E.L. Korn, Randomized clinical trials with biomarkers: design issues, J. Natl. Cancer Inst. 102 (2010) 152–160.

[12] B. Friedlin, E.L. Korn, Biomarker enrichment strategies: matching trial design to biomarker credentials, Nat. Rev. Clin. Oncol. 11 (2014) 81–90.

[13] J. Woodcock, L.B. Vogelstein, N. Steven, Research methods to change clinical practice for patients with rare cancers, Lancet Oncol. 17 (2016) e70–e80.

[14] C. Robert, et al., Pembrolizumab versus ipilimumab in advanced melanoma, N. Engl. J. Med. 372 (2015) 2521–2532.

[15] S.M. Malik, et al., Consensus report of a joint NCI thoracic malignancy steering committee: the era of genomic medicine, J. Clin. Oncol. 33 (2015) 975–987.

[16] B. Vogelstein, et al., Cancer genome landscapes, Science 339 (2013) 1546–1558.

[17] A.D. Barker, et al., I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant personalized medicine, Clin. Trials 5 (2008) 181–193.

[18] E.S. Kim, et al., The BATTLE trial: personalizing therapy for lung cancer, Canc. Discov. 1 (2011) 44–53.

[19] E.L. Korn, et al., An overview of the design and conduct of the BATTLE trials, Clin. Cancer. Oncol. 4 (2015) 33.

[20] A.D. Barker, et al., I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy, Clin. Pharmacol. Therapeut. 86 (2009) 97–100.

[21] I.W. Park, et al., Adjuvant radiation of neoadjuvant early breast cancer, N. Engl. J. Med. 375 (2011) 11–22.

[22] C. Robert, et al., Pembrolizumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med. 373 (2015) 123–135.

[23] R. Simon, et al., The Bayesian basket design for genomic variant-driven phase II trials, Semin. Oncol. 43 (2016) 13–18.

[24] S.J. Mandrekar, S.E. Dahlberg, R. Simon, Improving Clinical Trial Efficiency: Thinking outside the Box, American Society of Clinical Oncology Educational, 2015 Book e141-e147.

[25] B.P. Hobbs, N. Chen, J.J. Lee, Controlled multi-arm platform design using predictive probability, Stat. Math. Med. Res. 27 (2016) 65–78.

[26] M.C. Heinrich, et al., Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitiv e-Resinse kinases, Res. 14 (2008) 2717–2725.

[27] D.M. Hyman, et al., Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials, Drug Discov. Today. 20 (2015) 1422–1428.

[28] S.M. Swain, et al., Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, N. Engl. J. Med. 364 (2011) 2057–2065.

[29] R. Simon, et al., The Bayesian basket design for genomic variant-driven phase II trials, Semin. Oncol. 43 (2016) 13–18.

[30] S.J. Mandrekar, S.E. Dahlberg, R. Simon, Improving Clinical Trial Efficiency: Thinking outside the Box, American Society of Clinical Oncology Educational, 2015 Book e141-e147.

[31] B.P. Hobbs, N. Chen, J.J. Lee, Controlled multi-arm platform design using predictive probability, Stat. Math. Med. Res. 27 (2016) 65–78.

[32] M.C. Heinrich, et al., Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive-Resinse kinases, Res. 14 (2008) 2717–2725.

[33] D.M. Hyman, et al., Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials, Drug Discov. Today. 20 (2015) 1422–1428.

[34] A. Berry, The Brave New World of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research, Molecular Oncology 9 (2015) 951–959.

[35] S.M. Malik, et al., Consensus report of a joint NCI thoracic malignancy steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of ‘master protocols’ in lung cancer, J. Thorac. Oncol. 9 (2014) 1443–1444.

[36] L.A. Renfro, S.J. Mandrekar, Definitions and statistical properties of master protocols for personalized medicine in oncology, J. Biopharm. Stat. 6 (2017) 1–12.

[37] D.A. Berry, The Brave New World of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research, Molecular Oncology 9 (2015) 951–959.

[38] B.P. Hobbs, N. Chen, J.J. Lee, Controlled multi-arm platform design using predictive probability, Stat. Math. Med. Res. 27 (2016) 65–78.

[39] M.C. Heinrich, et al., Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive-Resinse kinases, Res. 14 (2008) 2717–2725.

[40] D.M. Hyman, et al., Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials, Drug Discov. Today. 20 (2015) 1422–1428.
simultaneous investigation of multiple tumor types in one study, Stat. Biopharm. Res. 8 (2016) 248–257.

[65] J. Lin, V. Bunn, Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials, Contemp. Clin. Trials 54 (2017) 48–59.

[66] S. Ventz, et al., Bayesian response-adaptive designs for basket trials, Biometrics 73 (2017) 905–915.

[67] S. Liu, J. Lee, An overview of the design and conduct of the BATTLE trials, Chin. Clin. Oncol. 4 (2015), http://cco.amegroups.com/article/view/6846/8607 , Accessed date: 9 October 2018.

[68] A.M. Kaizer, B.P. Hobbs, J.S. Koopmeiners, A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies, Biometrics (2018), https://doi.org/10.1111/biom.12841 (Epub ahead of print).

[69] P. Ghosh, et al., Design and monitoring of multi-arm multi-stage clinical trials, Biometrics 73 (2017) 1289–1299.

[70] D.A. Berry, Bayesian clinical trials, Nat. Rev. Drug Discov. 5 (2006) 27–36.

[71] B. Freidlin, Adaptive randomization versus interim monitoring, J. Clin. Oncol. 31 (2013) 969–978.

[72] E.L. Korn, B. Freidlin, Outcome-adaptive randomization: is it useful? J. Clin. Oncol. 29 (2011) 771–776.

[73] S.C. Chow, M. Chang, Adaptive Design Methods in Clinical Trials, second ed., Chapman & Hall/CRC, USA, 2011.

[74] Randomized, Embedded, Multifactorial adaptive platform trial for community-acquired Pneumonia (REMAP-CAP), https://clinicaltrials.gov/ct2/show/NCT02735707?term=NCT02735707&rank=1, (2017) , Accessed date: 27 December 2017.

[75] Antivirals for influenza Like Illness? An rCt of Clinical and Cost effectiveness in primary CarE (ALIC4E), http://www.prepare-europe.eu/About-us/Workpackages/Workpackage-6, 2018 (accessed 5 April 2018).

[76] The PREVAIL II writing group, for the Multi-National PREVAIL II Study Team, A randomized, controlled trial of ZMapp for Ebola virus infection, N. Engl. J. Med. 375 (2016) 1448–1456.

[77] C.W. Ritchie, et al., Development of interventions for the secondary prevention of Alzheimer’s dementia: the European Prevention of Alzheimer’s Dementia (EPAD) project, The Lancet Psychiatry 3 (2016) 179–186.

[78] R.J. Bateman, et al., The DIAN-TU Next Generation Alzheimer’s prevention trial: adaptive design and disease progression model, Alzheimer’s Dementia 13 (2017) 8–19.

[79] N. Takebe, L. McShane, B. Conley, Biomarkers: exceptional responders-discovering predictive biomarkers, Nat. Rev. Clin. Oncol. 12 (2015) 132–134.